Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Amid Litigation
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $34.00 price target on Ocular Therapeutix (NASDAQ: OCUL).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
